Trevi Therapeutics, Inc. Common Stock Earnings Dividend

Trevi Therapeutics, Inc. Common Stock’s revenue jumped NaN% since last year same period to $0Mn in the Q2 2026. On a quarterly growth basis, Trevi Therapeutics, Inc. Common Stock has generated NaN% jump in its revenue since last 3-months.

Trevi Therapeutics, Inc. Common Stock’s net profit fell -44.68% since last year same period to $-17.8Mn in the Q2 2026. On a quarterly growth basis, Trevi Therapeutics, Inc. Common Stock has generated -34.91% fall in its net profits since last 3-months.

Trevi Therapeutics, Inc. Common Stock’s net profit margin jumped NaN% since last year same period to -Inf% in the Q2 2026. On a quarterly growth basis, Trevi Therapeutics, Inc. Common Stock has generated NaN% jump in its net profit margins since last 3-months.

Trevi Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at -0.11 - a -57.14% fall from last quarter’s estimates.

Trevi Therapeutics, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at -0.11.

Trevi Therapeutics, Inc. Common Stock’s earning per share (EPS) fell -22.22% since last year same period to -0.11 in the Q2 2026. This indicates that the Trevi Therapeutics, Inc. Common Stock has generated -22.22% annual rate of fall in its earning per share (EPS) in the last 4 quarters.